Ultralife Corporation reported a revenue of $33.2 million for the third quarter ended September 30, 2022, representing a 52.7% increase compared to the same period last year. The company experienced an operating loss of $0.6 million and an adjusted EBITDA of $1.3 million.
Government/defense revenue doubled year-over-year.
Total company revenue increased by 53% due to government/defense revenue and the addition of Excell.
Backlog now exceeds $100 million, positioning the company well for near-term revenue increases.
Gross margins and profitability were pressured by production inefficiencies associated with supply chain disruptions and input cost inflation.
Ultralife is positioned well for near-term revenue increases and remains committed to advancing several transformational projects and new product opportunities to drive long-term revenue growth.